Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cellectar Biosciences, Inc. (CLRB : NSDQ)
 
 • Company Description   
Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin.

Number of Employees: 12

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.36 Daily Weekly Monthly
20 Day Moving Average: 157,591 shares
Shares Outstanding: 61.10 (millions)
Market Capitalization: $22.06 (millions)
Beta: 1.58
52 Week High: $1.84
52 Week Low: $0.34
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -42.68% -35.45%
12 Week -28.11% -20.97%
Year To Date -45.62% -33.55%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
100 CAMPUS DRIVE
-
FLORHAM PARK,NJ 07932
USA
ph: 608-441-8120
fax: 608-441-8121
investors@cellectar.com http://www.cellectar.com
 
 • General Corporate Information   
Officers
James V. Caruso - Chief Executive Officer
Chad J. Kolean - Chief Financial Officer
Frederick W. Driscoll - Director
Asher Alban Chanan-Khan - Director
Stefan D. Loren - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 15117F500
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 61.10
Most Recent Split Date: 7.00 (0.10:1)
Beta: 1.58
Market Capitalization: $22.06 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.40 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.85
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 23.08%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -73.53
12/31/21 - -67.83
09/30/21 - -60.05
ROA
03/31/22 - -60.18
12/31/21 - -53.03
09/30/21 - -42.90
Current Ratio
03/31/22 - 6.75
12/31/21 - 9.17
09/30/21 - 13.07
Quick Ratio
03/31/22 - 6.75
12/31/21 - 9.17
09/30/21 - 13.07
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.42
12/31/21 - 0.52
09/30/21 - 0.61
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©